Highlights
Higher baseline total testosterone is independently associated with a 26% reduction in cardiovascular risk among men with type 2 diabetes.
In men achieving significant weight loss (at least 7%), increases in Sex Hormone-Binding Globulin (SHBG) correlate with a 53% reduction in cardiovascular events.
For men with minimal weight loss, rising estradiol levels are linked to a nearly two-fold increase in cardiovascular risk.
No significant associations between sex hormones and cardiovascular outcomes were detected in women with type 2 diabetes, suggesting distinct sexual dimorphism in metabolic-hormonal pathways.
Introduction: The Intersection of Endocrinology and Cardiology
The relationship between sex hormones and cardiovascular (CV) health has long been a subject of intense clinical scrutiny. In patients with type 2 diabetes (T2D), this relationship is further complicated by metabolic dysfunction, obesity, and systemic inflammation. Historically, low testosterone levels in men have been recognized as a hallmark of metabolic syndrome and T2D, yet whether these hormonal profiles serve as active drivers of cardiovascular disease or merely as biomarkers of poor health remains a point of debate. The recent cohort study derived from the Look AHEAD (Action for Health in Diabetes) trial provides critical insights into how baseline hormone levels and intervention-induced hormonal changes influence long-term cardiovascular outcomes.
Background: The Disease Burden and the Look AHEAD Context
Type 2 diabetes is a major independent risk factor for cardiovascular disease, which remains the leading cause of morbidity and mortality in this population. Beyond glycemic control, clinicians must manage a constellation of risk factors, including dyslipidemia, hypertension, and obesity. Emerging evidence suggests that the endocrine milieu—specifically the balance of androgens and estrogens—plays a pivotal role in vascular health and adipocyte function. The Look AHEAD trial, originally designed to evaluate the effects of an intensive lifestyle intervention (ILI) on cardiovascular outcomes, offers a unique longitudinal platform to investigate these associations over an extended period. This specific analysis focuses on 2,260 adults, examining how sex hormones and sex hormone-binding globulin (SHBG) at baseline and their one-year changes predict future CV events.
Study Design and Methodology
This prospective cohort study utilized data from the Look AHEAD trial, a multi-center randomized controlled trial. The sub-analysis included 2,260 participants with T2D who had available measurements for sex hormones. The primary exposures were total testosterone (TT), estradiol (E2), and SHBG. Measurements were taken at baseline and after one year of follow-up. The researchers categorized baseline levels and one-year changes into sex-specific tertiles. The primary endpoint was the occurrence of major cardiovascular events, with a median follow-up that captured 488 events. A key feature of this study was the interaction analysis between hormonal changes and the degree of weight loss, specifically using a 7% weight loss threshold, which is clinically significant for metabolic improvement.
Key Findings: Testosterone as a Protective Sentinel in Men
The results for male participants were striking. Men in the highest tertile of baseline total testosterone experienced a significantly lower risk of cardiovascular events compared to those in the lowest tertile (HR 0.74; 95% CI 0.56-0.97). This reinforces the hypothesis that maintaining physiological testosterone levels may be cardioprotective in the context of T2D. However, the study adds a layer of complexity by examining the dynamic changes in these hormones over time.
The SHBG and Weight Loss Interaction
One of the most significant findings involved SHBG, a protein primarily produced in the liver that transports sex hormones. In men who achieved a weight loss of 7% or more, an increase in SHBG at one year was associated with a profound 53% reduction in CV risk (HR 0.47; 95% CI 0.26-0.85). SHBG is often considered a surrogate marker for insulin sensitivity; therefore, its rise during weight loss likely reflects a systemic improvement in metabolic health and a reduction in hepatic fat, which in turn translates to better cardiovascular outcomes.
The Estradiol Paradox in Men
Conversely, the study highlighted a potential risk associated with estradiol in men who did not achieve significant weight loss. In the group with less than 7% weight loss, increases in estradiol were linked to a higher risk of CV events (HR 1.88 for the highest tertile vs. the lowest). This finding is biologically plausible when considering the aromatization process, where testosterone is converted into estradiol in adipose tissue. In the absence of weight loss, rising estradiol may signify persistent adiposity and a dysfunctional hormonal environment that promotes vascular inflammation.
The Gender Gap: Findings in Women
Interestingly, the study found no significant associations between sex hormones (testosterone, SHBG, or estradiol) and cardiovascular events in women. This lack of association persisted even after adjusting for weight loss and other metabolic variables. These results underscore the fundamental biological differences in how sex hormones mediate cardiovascular risk between the sexes. In women with T2D, especially post-menopausal women who made up a large portion of the cohort, other factors such as the loss of endogenous estrogen’s protective effects or the specific impact of insulin resistance on the female vasculature may override the predictive value of circulating hormone levels measured in this study.
Expert Commentary and Clinical Implications
The Look AHEAD findings suggest that for men with T2D, the hormonal profile is not static but interacts dynamically with lifestyle changes. Clinicians should view low baseline testosterone and low SHBG as red flags for elevated CV risk. The data also suggests that weight loss is the primary driver of hormonal normalization. When weight loss is achieved, the subsequent rise in SHBG serves as a favorable prognostic indicator. For men struggling to lose weight, the rise in estradiol may be a marker of an adverse metabolic state that requires more aggressive cardiovascular risk management.
However, some caution is warranted. While higher testosterone is associated with lower risk, this observational study does not prove that testosterone replacement therapy (TRT) will reduce CV events in this population. The TRAVERSE trial recently showed the safety of TRT in men with hypogonadism, but the specific benefit for CV risk reduction in T2D patients requires further targeted clinical trials. Furthermore, the study’s reliance on total testosterone rather than free testosterone (the biologically active fraction) may be a limitation, although total testosterone remains the standard clinical measure.
Conclusion
The study by Gisinger et al. clarifies the sex-specific nature of cardiovascular risk in type 2 diabetes. In men, the hormonal axis—encompassing testosterone, SHBG, and estradiol—is a potent predictor of cardiovascular health, particularly when viewed through the lens of weight loss success. For women, the drivers of cardiovascular risk appear to be independent of these specific hormonal measures, necessitating different investigative approaches. These findings advocate for a personalized, sex-aware approach to diabetes management, where hormonal monitoring could potentially refine risk stratification and motivate lifestyle interventions.
Funding and References
The Look AHEAD trial was funded by the National Institutes of Health (NIH), including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Additional support was provided by the Centers for Disease Control and Prevention (CDC).
References:
1. Gisinger T, He JH, Oyeka CP, et al. Sex Hormones and Cardiovascular Risk in Type 2 Diabetes: Cohort Study of the Look AHEAD Trial. Diabetes Care. 2026;49(3):497-501. PMID: 41582527.
2. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154.
3. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117.
